Skip to main content
Erschienen in: Tumor Biology 3/2013

01.06.2013 | Research Article

Optimization of apparent diffusion coefficient measured by diffusion-weighted MRI for diagnosis of breast lesions presenting as mass and non-mass-like enhancement

verfasst von: Liuquan Cheng, Yuhan Bai, Jing Zhang, Mei Liu, Xiru Li, Ailiang Zhang, Xiaojing Zhang, Lin Ma

Erschienen in: Tumor Biology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to investigate the diagnostic value of the apparent diffusion coefficient (ADC), measured by diffusion-weighted magnetic resonance imaging (MRI), for the diagnosis of breast lesions presenting as mass and non-mass-like enhancement (NMLE). The breast MRI studies of 174 patients were reviewed retrospectively. A total of 188 histologically confirmed lesions were analyzed and classified into 127 mass enhancement (86 malignant and 41 benign) and 61 NMLE (42 malignant and 19 benign). The ADC values were measured using a spin-echo echo-planner-imaging (SE-EPI) sequence with b = 1,000 s/mm2. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis. The mean ADC was 0.99 ± 0.22 × 10−3 mm2/s for invasive cancer, 1.23 ± 0.33 × 10−3 mm2/s for ductal carcinoma in situ (DCIS), and 1.52 ± 0.35 × 10−3 mm2/s for benign adenosis. The mean ADC of all NMLE lesions was 1.44 ± 0.41 × 10−3 mm2/s, which is higher than the mean ADC of all mass lesions, 1.12 ± 0.33 × 10−3 mm2/s. In the ROC analysis, the optimal cutoff ADC value for differentiating benign from malignant lesions was 1.05 × 10−3 mm2/s for mass lesions and 1.35 × 10−3 mm2/s for NMLE. In conclusion, ADC values can be used for the diagnosis of invasive and DCIS as well as benign tumors. The NMLE lesions tend to have higher ADC values than mass lesions; therefore, the morphological appearance of a lesion needs to be considered when using the ADC value for diagnosis.
Literatur
1.
Zurück zum Zitat Guo Y, Cai YQ, Cai ZL, Gao YG, An NY, Ma L, et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging. 2002;16:172–8.PubMedCrossRef Guo Y, Cai YQ, Cai ZL, Gao YG, An NY, Ma L, et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging. 2002;16:172–8.PubMedCrossRef
2.
Zurück zum Zitat Yuan J, Mei CS, Panych LP, McDannold NJ, Madore B. Towards fast and accurate temperature mapping with proton resonance frequency-based MR thermometry. Quant Imaging Med Surg. 2012;2:21–32.PubMed Yuan J, Mei CS, Panych LP, McDannold NJ, Madore B. Towards fast and accurate temperature mapping with proton resonance frequency-based MR thermometry. Quant Imaging Med Surg. 2012;2:21–32.PubMed
3.
Zurück zum Zitat Cheng L, Li X. Breast Imaging Reporting and Data System (BI-RADS) of magnetics resonance imaging: breast mass. Gland Surg. 2012;1:62–74. Cheng L, Li X. Breast Imaging Reporting and Data System (BI-RADS) of magnetics resonance imaging: breast mass. Gland Surg. 2012;1:62–74.
4.
Zurück zum Zitat Ishikawa T, Shimizu D, Kito A, Ota I, Sasaki T, Tanabe M, et al. Breast cancer manifested by hematologic disorders. J Thorac Dis. 2012;4:650–4.PubMed Ishikawa T, Shimizu D, Kito A, Ota I, Sasaki T, Tanabe M, et al. Breast cancer manifested by hematologic disorders. J Thorac Dis. 2012;4:650–4.PubMed
5.
Zurück zum Zitat Cheng L, Li X. Breast magnetic resonance imaging: focus/foci. Gland Surg. 2012;1:136–8. Cheng L, Li X. Breast magnetic resonance imaging: focus/foci. Gland Surg. 2012;1:136–8.
6.
Zurück zum Zitat Winston GP. The physical and biological basis of quantitative parameters derived from diffusion MRI. Quant Imaging Med Surg. 2012;2:254–65.PubMed Winston GP. The physical and biological basis of quantitative parameters derived from diffusion MRI. Quant Imaging Med Surg. 2012;2:254–65.PubMed
7.
Zurück zum Zitat Partridge SC, DeMartini WB, Kurland BF, Eby PR, White SW, Lehman CD. Quantitative diffusion-weighted imaging as an adjunct to conventional breast MRI for improved positive predictive value. AJR Am J Roentgenol. 2009;193:1716–22.PubMedCrossRef Partridge SC, DeMartini WB, Kurland BF, Eby PR, White SW, Lehman CD. Quantitative diffusion-weighted imaging as an adjunct to conventional breast MRI for improved positive predictive value. AJR Am J Roentgenol. 2009;193:1716–22.PubMedCrossRef
8.
Zurück zum Zitat Ei Khouli RH, Jacobs MA, Mezban SD, Huang P, Kamel IR, Macura KJ, et al. Diffusion-weighted imaging improves the diagnostic accuracy of conventional 3.0-T breast MR imaging. Radiology. 2010;256:64–73.PubMedCrossRef Ei Khouli RH, Jacobs MA, Mezban SD, Huang P, Kamel IR, Macura KJ, et al. Diffusion-weighted imaging improves the diagnostic accuracy of conventional 3.0-T breast MR imaging. Radiology. 2010;256:64–73.PubMedCrossRef
9.
Zurück zum Zitat Partridge SC, Demartini WB, Kurland BF, Eby PR, White SW, Lehman CD. Differential diagnosis of mammographically and clinically occult breast lesions on diffusion-weighted MRI. J Magn Reson Imaging. 2010;31:562–70.PubMedCrossRef Partridge SC, Demartini WB, Kurland BF, Eby PR, White SW, Lehman CD. Differential diagnosis of mammographically and clinically occult breast lesions on diffusion-weighted MRI. J Magn Reson Imaging. 2010;31:562–70.PubMedCrossRef
10.
Zurück zum Zitat Partridge SC, Mullins CD, Kurland BF, Allain MD, DeMartini WB, Eby PR, et al. Apparent diffusion coefficient values for discriminating benign and malignant breast MRI lesions: effects of lesion type and size. AJR Am J Roentgenol. 2010;194:1664–73.PubMedCrossRef Partridge SC, Mullins CD, Kurland BF, Allain MD, DeMartini WB, Eby PR, et al. Apparent diffusion coefficient values for discriminating benign and malignant breast MRI lesions: effects of lesion type and size. AJR Am J Roentgenol. 2010;194:1664–73.PubMedCrossRef
11.
Zurück zum Zitat Yabuuchi H, Matsuo Y, Okafuji T, Kamitani T, Soeda H, Setoguchi T, et al. Enhanced mass on contrast-enhanced breast MR imaging: lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. J Magn Reson Imaging. 2008;28:1157–65.PubMedCrossRef Yabuuchi H, Matsuo Y, Okafuji T, Kamitani T, Soeda H, Setoguchi T, et al. Enhanced mass on contrast-enhanced breast MR imaging: lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. J Magn Reson Imaging. 2008;28:1157–65.PubMedCrossRef
12.
Zurück zum Zitat Yabuuchi H, Matsuo Y, Kamitani T, Setoguchi T, Okafuji T, Soeda H, et al. Non-mass-like enhancement on contrast-enhanced breast MR imaging: lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. Eur J Radiol. 2010;75:e126–32. doi:10.1016/j.ejrad.2009.09.013.PubMedCrossRef Yabuuchi H, Matsuo Y, Kamitani T, Setoguchi T, Okafuji T, Soeda H, et al. Non-mass-like enhancement on contrast-enhanced breast MR imaging: lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. Eur J Radiol. 2010;75:e126–32. doi:10.​1016/​j.​ejrad.​2009.​09.​013.PubMedCrossRef
13.
Zurück zum Zitat Kuroki-Suzuki S, Kuroki Y, Nasu K, Nawano S, Moriyama N, Okazaki M. Detecting breast cancer with non-contrast MR imaging: combining diffusion-weighted and STIR imaging. Magn Reson Med Sci. 2007;6:21–7.PubMedCrossRef Kuroki-Suzuki S, Kuroki Y, Nasu K, Nawano S, Moriyama N, Okazaki M. Detecting breast cancer with non-contrast MR imaging: combining diffusion-weighted and STIR imaging. Magn Reson Med Sci. 2007;6:21–7.PubMedCrossRef
14.
Zurück zum Zitat Baltzer PA, Benndorf M, Dietzel M, Gajda M, Camara O, Kaiser WA. Sensitivity and specificity of unenhanced MR mammography (DWI combined with T2-weighted TSE imaging, ueMRM) for the differentiation of mass lesions. Eur Radiol. 2010;20:1101–10. doi:10.1007/s00330-009-1654-5.PubMedCrossRef Baltzer PA, Benndorf M, Dietzel M, Gajda M, Camara O, Kaiser WA. Sensitivity and specificity of unenhanced MR mammography (DWI combined with T2-weighted TSE imaging, ueMRM) for the differentiation of mass lesions. Eur Radiol. 2010;20:1101–10. doi:10.​1007/​s00330-009-1654-5.PubMedCrossRef
15.
Zurück zum Zitat Woodhams R, Matsunaga K, Iwabuchi K, Kan S, Hata H, Kuranami M, et al. Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr. 2005;29:644–9.PubMedCrossRef Woodhams R, Matsunaga K, Iwabuchi K, Kan S, Hata H, Kuranami M, et al. Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr. 2005;29:644–9.PubMedCrossRef
16.
Zurück zum Zitat Yoshikawa MI, Ohsumi S, Sugata S, Kataoka M, Takashima S, Mochizuki T, et al. Relation between cancer cellularity and apparent diffusion coefficient values using diffusion-weighted magnetic resonance imaging in breast cancer. Radiat Med. 2008;26:222–6. doi:10.1007/s11604-007-0218-3.PubMedCrossRef Yoshikawa MI, Ohsumi S, Sugata S, Kataoka M, Takashima S, Mochizuki T, et al. Relation between cancer cellularity and apparent diffusion coefficient values using diffusion-weighted magnetic resonance imaging in breast cancer. Radiat Med. 2008;26:222–6. doi:10.​1007/​s11604-007-0218-3.PubMedCrossRef
17.
Zurück zum Zitat Imamura T, Isomoto I, Sueyoshi E, Yano H, Uga T, Abe K, et al. Diagnostic performance of ADC for non-mass-like breast lesions on MR imaging. Magn Reson Med Sci. 2010;9:217–25.PubMedCrossRef Imamura T, Isomoto I, Sueyoshi E, Yano H, Uga T, Abe K, et al. Diagnostic performance of ADC for non-mass-like breast lesions on MR imaging. Magn Reson Med Sci. 2010;9:217–25.PubMedCrossRef
19.
Zurück zum Zitat Goto M, Ito H, Akazawa K, Kubota T, Kizu O, Yamada K, et al. Diagnosis of breast tumors by contrast-enhanced MR imaging: comparison between the diagnostic performance of dynamic enhancement patterns and morphologic features. J Magn Reson Imaging. 2007;25:104–12. doi:10.1002/jmri.20812.PubMedCrossRef Goto M, Ito H, Akazawa K, Kubota T, Kizu O, Yamada K, et al. Diagnosis of breast tumors by contrast-enhanced MR imaging: comparison between the diagnostic performance of dynamic enhancement patterns and morphologic features. J Magn Reson Imaging. 2007;25:104–12. doi:10.​1002/​jmri.​20812.PubMedCrossRef
20.
Zurück zum Zitat Jansen SA, Fan X, Karczmar GS, Abe H, Schmidt RA, Giger M, et al. DCEMRI of breast lesions: is kinetic analysis equally effective for both mass and nonmass-like enhancement. Med Phys. 2008;35:3102–9. doi:10.1118/1.2936220.PubMedCrossRef Jansen SA, Fan X, Karczmar GS, Abe H, Schmidt RA, Giger M, et al. DCEMRI of breast lesions: is kinetic analysis equally effective for both mass and nonmass-like enhancement. Med Phys. 2008;35:3102–9. doi:10.​1118/​1.​2936220.PubMedCrossRef
21.
Zurück zum Zitat Newell D, Nie K, Chen JH, Hsu CC, Yu HJ, Nalcioglu O, et al. Selection of diagnostic features on breast MRI to differentiate between malignant and benign lesions using computer-aided diagnosis: differences in lesions presenting as mass and non-mass-like enhancement. Eur Radiol. 2010;20:771–81. doi:10.1007/s00330-009-1616-y.PubMedCrossRef Newell D, Nie K, Chen JH, Hsu CC, Yu HJ, Nalcioglu O, et al. Selection of diagnostic features on breast MRI to differentiate between malignant and benign lesions using computer-aided diagnosis: differences in lesions presenting as mass and non-mass-like enhancement. Eur Radiol. 2010;20:771–81. doi:10.​1007/​s00330-009-1616-y.PubMedCrossRef
23.
Zurück zum Zitat Hatakenaka M, Soeda H, Yabuuchi H, Matsuo Y, Kamitani T, Oda Y, et al. Apparent diffusion coefficients of breast tumors: clinical application. Magn Reson Med Sci. 2008;7:23–9.PubMedCrossRef Hatakenaka M, Soeda H, Yabuuchi H, Matsuo Y, Kamitani T, Oda Y, et al. Apparent diffusion coefficients of breast tumors: clinical application. Magn Reson Med Sci. 2008;7:23–9.PubMedCrossRef
26.
Zurück zum Zitat Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology. 1986;161:401–7.PubMed Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology. 1986;161:401–7.PubMed
27.
Zurück zum Zitat Gururajan M, Posadas EM, Chung LW. Future perspectives of prostate cancer therapy. Transl Androl Urol. 2012;1:19–32.PubMed Gururajan M, Posadas EM, Chung LW. Future perspectives of prostate cancer therapy. Transl Androl Urol. 2012;1:19–32.PubMed
28.
Zurück zum Zitat Yuen S, Yamada K, Goto M, Nishida K, Takahata A, Nishimura T. Microperfusion-induced elevation of ADC is suppressed after contrast in breast carcinoma. J Magn Reson Imaging. 2009;29:1080–4.PubMedCrossRef Yuen S, Yamada K, Goto M, Nishida K, Takahata A, Nishimura T. Microperfusion-induced elevation of ADC is suppressed after contrast in breast carcinoma. J Magn Reson Imaging. 2009;29:1080–4.PubMedCrossRef
Metadaten
Titel
Optimization of apparent diffusion coefficient measured by diffusion-weighted MRI for diagnosis of breast lesions presenting as mass and non-mass-like enhancement
verfasst von
Liuquan Cheng
Yuhan Bai
Jing Zhang
Mei Liu
Xiru Li
Ailiang Zhang
Xiaojing Zhang
Lin Ma
Publikationsdatum
01.06.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 3/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0682-6

Weitere Artikel der Ausgabe 3/2013

Tumor Biology 3/2013 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.